TransCode starts phase 2a trial for colorectal cancer drug

May 27, 2026 8:04 AM

TransCode Therapeutics Inc. (NASDAQ: RNAZ) has initiated a Phase 2a clinical trial to evaluate its drug candidate TTX-MC138 in patients ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found